In previous studies, Magnusson et al. [18] reported that cystatin C might contribute to development of MetS by affecting metabolic parameters in general population, and Vigil et al. [20] showed that circulating cystatin C included several non-GFR determinants by multiple linear regression analysis in a hypertension population with a larger proportion of MetS. The gene discussed is CST3; the disease is metabolic syndrome.